Doctors are moving away from propofol as a first-line ICU sedative because of three converging pressures: updated clinical guidelines now favor alternatives, a rare but devastating complication called propofol infusion syndrome carries mortality rates as high as 85 percent, and persistent drug shortages have made propofol unreliable to stock. The March 2025 update to the Society of Critical Care Medicine’s PADIS guidelines made it official, issuing a conditional recommendation for dexmedetomidine over propofol when light sedation and delirium reduction are clinical priorities. For families navigating ICU care for an older loved one, particularly someone living with dementia or at elevated risk for delirium, this shift has real consequences worth understanding. The change did not happen overnight. Propofol has been a workhorse of ICU sedation for decades, valued for its rapid onset and quick offset.
But accumulating evidence about its metabolic risks, combined with growing recognition that deep sedation itself harms older and cognitively vulnerable patients, has steadily eroded its default status. Meanwhile, supply chain failures have forced clinicians to become fluent with alternatives whether they wanted to or not. This article covers the clinical guidelines driving the change, the specific dangers of propofol infusion syndrome, how dexmedetomidine compares in practice, emerging alternatives on the horizon, and what families should know when a loved one faces ICU sedation. The implications extend well beyond pharmacy logistics. For patients with dementia or other forms of cognitive impairment, the choice of sedative can influence delirium risk, time on a ventilator, and the trajectory of recovery. Understanding why this shift is happening puts families in a better position to ask informed questions during some of the most difficult conversations in medicine.
Table of Contents
- Why Are ICU Doctors Choosing Lighter Sedation Over Propofol?
- What Is Propofol Infusion Syndrome and Why Is It So Dangerous?
- How Dexmedetomidine Compares in Practice
- What Families Should Ask About ICU Sedation Choices
- Supply Shortages Are Forcing the Shift Whether Clinicians Are Ready or Not
- Ciprofol and Inhaled Sedatives as Emerging Options
- What This Means for the Future of Brain-Protective ICU Care
- Conclusion
- Frequently Asked Questions
Why Are ICU Doctors Choosing Lighter Sedation Over Propofol?
The short answer is that deep sedation causes measurable harm, and propofol tends to produce deeper sedation than clinicians now consider appropriate for most patients. The 2025 SCCM PADIS guidelines update, published in March 2025, covers five domains: anxiety (newly added to the framework), agitation and sedation, delirium, immobility, and sleep disruption. Across all five, the recommendations are conditional, meaning they should be tailored to individual patients rather than applied as blanket protocol. But the direction is clear. When the goal is light sedation and reduced delirium, dexmedetomidine is the preferred agent over propofol. This matters enormously for older adults and people with pre-existing cognitive impairment. ICU delirium, a state of acute confusion that can develop during critical illness, affects up to 80 percent of mechanically ventilated patients and is independently associated with longer hospital stays, higher mortality, and lasting cognitive decline.
For someone already living with dementia, a bout of ICU delirium can accelerate functional deterioration in ways that may never fully reverse. Propofol, by promoting deeper sedation, can mask delirium symptoms while simultaneously making them more likely to develop. Dexmedetomidine, by contrast, allows patients to remain more arousable and interactive, which helps clinical teams detect and manage delirium earlier. The comparison is not purely theoretical. The landmark SPICE III trial found that patients sedated with dexmedetomidine were demonstrably more interactive than those receiving other sedatives. However, that same trial showed no significant difference in duration of mechanical ventilation, ICU or hospital length of stay, or short-term mortality. This is a critical nuance. Dexmedetomidine appears to reduce delirium and improve time spent at target sedation levels, but it has not yet been shown to change the hard outcomes that families care about most, like survival and time in the hospital.
What Is Propofol Infusion Syndrome and Why Is It So Dangerous?
Propofol infusion syndrome, or PRIS, is the clinical complication that has done the most to undermine confidence in long-duration propofol use. It is rare. The incidence is approximately 1.1 percent in critically ill adults receiving propofol for more than 24 hours, based on a study of 1,017 patients. But rare does not mean ignorable when the consequences are this severe. Mortality from PRIS can reach up to 85 percent, placing it among the deadliest drug-related adverse events encountered in intensive care. The syndrome manifests as a cascade of metabolic failures. In documented cases, metabolic acidosis appears in 86 percent of patients who develop PRIS, cardiac dysfunction in 88 percent, rhabdomyolysis (the breakdown of muscle tissue) in 45 percent, renal failure in 37 percent, and hypertriglyceridemia in 15 percent.
The risk escalates with dose and duration. Patients receiving propofol for more than 72 hours see the incidence climb to 4.1 percent, and doses exceeding 5 mg/kg/hr for more than 48 hours are considered a significant danger zone. A 2025 study published in Scientific Reports further characterized the biochemical and pharmacological risk markers associated with high-dose propofol exposure, advancing the field’s ability to identify vulnerable patients before the syndrome takes hold. However, context matters here. PRIS is overwhelmingly a problem of prolonged, high-dose infusion, which is the pattern seen in ICU sedation rather than in brief procedural anesthesia. A patient undergoing a short surgical procedure with propofol faces a fundamentally different risk profile than someone sedated in the ICU for days. Families should understand this distinction. The push away from propofol is specifically about its use as a sustained sedative in critical care, not a wholesale rejection of the drug in all clinical settings.
How Dexmedetomidine Compares in Practice
Dexmedetomidine works through an entirely different mechanism than propofol. It is an alpha-2 adrenergic agonist that produces sedation resembling natural sleep, allowing patients to be roused for neurological assessments and to participate in early mobilization. This quality makes it particularly attractive for cognitively vulnerable populations, including older adults with dementia, where maintaining the ability to interact with care teams is not a luxury but a clinical priority. The 2025 PADIS guidelines note that dexmedetomidine reduces delirium and improves time spent at target sedation levels compared to propofol, and that these benefits are considered to outweigh the increased risk of bradycardia, a slowing of the heart rate that is dexmedetomidine’s primary cardiovascular side effect. For most patients, bradycardia can be monitored and managed. But it is not trivial.
In patients with pre-existing cardiac conduction abnormalities or those on other heart-rate-lowering medications, dexmedetomidine requires careful hemodynamic monitoring. There is another important limitation. A 2025 randomized clinical trial, the A2B trial, found that neither dexmedetomidine nor clonidine was superior to propofol in reducing time to successful extubation. In other words, while dexmedetomidine may keep patients more awake and less delirious, it does not necessarily get them off the ventilator faster. This finding should temper expectations. The shift to dexmedetomidine is not a cure-all. It is a recalibration toward a sedation strategy that prioritizes cognitive preservation and delirium prevention, even when the blunt outcome metrics remain similar.
What Families Should Ask About ICU Sedation Choices
When a loved one, especially an older adult with cognitive impairment, faces mechanical ventilation and ICU sedation, families are often overwhelmed and unsure what questions are within their right to ask. The answer is: all of them. Understanding the sedation plan is as legitimate as understanding the ventilator settings or the antibiotic regimen. Start with the basics. Ask which sedative is being used and why. If the answer is propofol, ask about the anticipated duration and whether alternatives like dexmedetomidine have been considered, particularly if your family member has dementia or is at elevated risk for delirium.
Ask about the sedation target. The PADIS guidelines emphasize light sedation for most patients, meaning the goal should be a patient who can be aroused and can follow simple commands, not one who is deeply unconscious. Deep sedation should be reserved for specific clinical indications like severe acute respiratory distress syndrome or status epilepticus, not used as a default for staff convenience. The tradeoff families should understand is straightforward. Dexmedetomidine offers better delirium prevention and a more interactive patient, but it carries a risk of bradycardia and may not shorten the time on the ventilator. Propofol offers reliable deep sedation and rapid offset, but with the risk of PRIS in prolonged use and a higher likelihood of masking or worsening delirium. Neither choice is wrong in all circumstances, but the conversation should happen explicitly rather than being left to automatic protocol.
Supply Shortages Are Forcing the Shift Whether Clinicians Are Ready or Not
Even without the guideline changes and safety concerns, many ICU teams would be moving away from propofol for a purely practical reason: they cannot reliably get it. Propofol remains on the American Society of Health-System Pharmacists drug shortage list. Hikma’s propofol vials in the 20 mL, 50 mL, and 100 mL sizes are on back order with no estimated release date. Teva discontinued its propofol product entirely in January 2023. These are not temporary blips. The shortage has been a recurring feature of critical care pharmacy for years. Supply constraints have forced ICU providers to become adept with alternatives including dexmedetomidine, midazolam, and inhaled sedatives.
This adaptation has been uneven. Dexmedetomidine is significantly more expensive than propofol, which creates budget pressure in facilities already stretched thin. Midazolam, the main benzodiazepine alternative, is itself associated with increased delirium risk, making it a poor substitute for the very population that stands to benefit most from the shift away from propofol. For dementia patients and other cognitively vulnerable groups, a propofol shortage that defaults to midazolam may actually worsen outcomes. The warning here is for families and advocates. Not all ICU sedation alternatives are created equal, and a drug shortage does not automatically lead to the best clinical choice. If propofol is unavailable and midazolam is being used instead, it is worth asking whether dexmedetomidine is an option, particularly for patients where delirium prevention should be a high priority.
Ciprofol and Inhaled Sedatives as Emerging Options
The next generation of ICU sedatives is already in clinical evaluation. Ciprofol, a structural analog of propofol, showed comparable efficacy and safety to propofol for ICU sedation in mechanically ventilated adults according to a June 2025 meta-analysis of randomized controlled trials. If ciprofol can replicate propofol’s clinical advantages while reducing the risk of PRIS, it could carve out a meaningful niche, though long-term safety data in prolonged infusion settings remains limited. On a completely different track, inhaled sedation is being tested as a viable ICU strategy.
The INSPiRE-ICU2 phase 3 trial is currently underway across 16 U.S. hospitals, enrolling 235 patients to compare inhaled isoflurane delivered via the Sedaconda ACD-S device against intravenous propofol. The trial is partly motivated by the ongoing sedative drug shortages themselves, an acknowledgment that the ICU sedation landscape needs more options, not fewer. For now, neither ciprofol nor inhaled isoflurane is ready for routine clinical use, but both represent a field actively searching for better answers.
What This Means for the Future of Brain-Protective ICU Care
The broader trajectory is unmistakable. ICU medicine is moving toward sedation strategies that protect the brain rather than simply quieting the patient. This evolution is especially significant for the dementia care community, where any additional cognitive insult during a critical illness can have disproportionate long-term consequences.
The 2025 PADIS update, with its new inclusion of anxiety as a formal domain and its continued emphasis on delirium prevention, signals that cognitive outcomes are becoming central to how intensivists evaluate sedation protocols. Looking ahead, the ideal ICU sedation strategy for cognitively vulnerable patients will likely involve multimodal approaches, combining pharmacological agents like dexmedetomidine with non-pharmacological interventions such as early mobilization, sleep hygiene protocols, and family engagement at the bedside. The question will no longer be simply which drug to infuse, but how to create an ICU environment that minimizes the cognitive cost of critical illness. For families navigating these decisions, the most important thing to know is that they have a right to participate in that conversation and that the evidence increasingly supports asking for lighter, brain-friendlier sedation.
Conclusion
The shift away from propofol as a default ICU sedative reflects a genuine evolution in critical care thinking. Updated 2025 SCCM guidelines now conditionally recommend dexmedetomidine for light sedation and delirium prevention. The risk of propofol infusion syndrome, though rare, carries mortality rates that no clinician takes lightly. And persistent supply shortages have made propofol an unreliable foundation for sedation protocols.
Together, these forces are reshaping how ICU teams approach one of their most fundamental decisions. For families of older adults and people living with dementia, this shift offers both an opportunity and a responsibility. The opportunity is that evidence-based alternatives to deep sedation are now guideline-endorsed and increasingly available. The responsibility is to ask questions, advocate for brain-protective sedation strategies, and understand that no single drug is perfect for every patient. The conversation about ICU sedation should happen before a crisis whenever possible, as part of advance care planning, and should be revisited with the clinical team whenever circumstances change.
Frequently Asked Questions
Is propofol being banned from ICU use?
No. Propofol remains an important sedative with specific clinical indications. The shift is away from its routine use as a default long-duration sedative, not an outright prohibition. It is still appropriate for short procedures and certain clinical scenarios where deep sedation is specifically required.
What is propofol infusion syndrome and how common is it?
Propofol infusion syndrome is a rare but potentially fatal metabolic complication that can develop during prolonged, high-dose propofol infusion. The incidence is approximately 1.1 percent in patients receiving propofol for more than 24 hours and rises to 4.1 percent after 72 hours. Mortality can reach up to 85 percent.
Is dexmedetomidine safe for elderly patients with dementia?
Dexmedetomidine is generally considered a safer option for cognitively vulnerable patients because it reduces delirium and allows patients to remain more arousable. However, it carries a risk of bradycardia and requires cardiac monitoring. Each patient’s cardiovascular status should be evaluated individually.
Will switching from propofol to dexmedetomidine help my family member get off the ventilator faster?
Current evidence, including the 2025 A2B trial, suggests that dexmedetomidine does not reduce time to successful extubation compared to propofol. Its primary advantages are in delirium prevention and maintaining lighter, more interactive sedation levels.
What should I ask the ICU team about sedation for my loved one?
Ask which sedative is being used, what the target sedation depth is, whether delirium prevention has been factored into the choice, and whether dexmedetomidine has been considered if propofol is the current agent. You have every right to understand and participate in these decisions.
Are there newer sedation drugs being developed?
Yes. Ciprofol, a structural analog of propofol, has shown comparable efficacy in early trials. Inhaled isoflurane is being tested in the INSPiRE-ICU2 phase 3 trial across 16 U.S. hospitals. Neither is yet available for routine clinical use, but both represent active areas of development.
